Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Eur J Contracept Reprod Health Care ; 26(3): 184-194, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33645377

ABSTRACT

PURPOSE: To evaluate the pharmacokinetics and pharmacodynamics of oestriol (E3) and trimegestone (TMG) in healthy women after application of three different vaginal rings over 21 days. The vaginal rings had a nominal delivery rate of 0.413/0.050 mg/day (Test 1), 0.311/0.090 mg/day (Test 2) and 0.209/0.137 mg/day (Test 3) E3/TMG. METHODS: Thirty-five healthy women were randomised to receive a single application of Test 1, 2 or 3 (Clinical Trial NCT03343912). The E3 and TMG plasma concentration was determined by LC-MS/MS. Oestradiol (E2) and progesterone (PG) serum concentrations, and bleeding patern were determined as pharmacodynamic parameters. Safety was assessed by evaluation of adverse events and local tolerability. RESULTS: The total and maximum exposure of E3 and TMG increased in a proportional ratio to dose. However, not in a magnitude which was expected from the dose differences for E3. During Test 2 and 3 treatment all E2 and PG values remained on a well suppressed level until end of treatment. E2 and PG serum levels increased distinctly earlier after ring removal with Test 1 compared to Test 2 and 3. Test 3 achieved 95.24% of "no bleeding" days under treatment followed by Test 1 (91.67%), and Test 2 (86.15%). CONCLUSIONS: The Test 3 formulation presented the best dose combination of E3/TMG for contraception. Moreover, all vaginal rings were well tolerated.


Subject(s)
Contraceptive Agents, Female/administration & dosage , Contraceptive Devices, Female , Estriol/pharmacology , Estriol/pharmacokinetics , Estrogens/metabolism , Promegestone/analogs & derivatives , Administration, Intravaginal , Adult , Chromatography, Liquid , Estradiol/blood , Estrogens/blood , Female , Humans , Progesterone/blood , Promegestone/pharmacokinetics , Promegestone/pharmacology , Tandem Mass Spectrometry
3.
Hum Reprod ; 33(11): 2131-2140, 2018 11 01.
Article in English | MEDLINE | ID: mdl-30265306

ABSTRACT

STUDY QUESTION: Which progesterone vaginal pessary dose regimen induces adequate secretory transformation of the endometrium, in comparison with progesterone vaginal gel and placebo? SUMMARY ANSWER: The best secretory transformation of the endometrium was observed during treatment with 400 mg progesterone vaginal pessaries, administered twice daily. WHAT IS KNOWN ALREADY: Vaginally administered progesterone is widely used for luteal phase support (LPS) in assisted reproductive techniques (ART). Although several vaginal formulations using various doses are available, little is known on the impact of formulation and doses at the endometrial level. STUDY DESIGN, SIZE, DURATION: The study had a randomised, observer-blind design and comprised two parts. The participants used study medication during two or three treatment periods, separated by washout periods. Subjects in Part 1 (n = 61 treated) received 200 mg progesterone vaginal pessaries twice daily (bid), 400 mg pessaries bid and the comparator 90 mg progesterone vaginal gel once daily (od) in a 3-way crossover design. Subjects in Part 2 (n = 64 treated) received 100 mg pessaries bid in one period and 400 mg pessaries od in the other period in a 2-way crossover design. A subgroup of these subjects (n = 22 treated) received placebo vaginal pessaries bid in a third period in a non-randomised manner. The study was performed from May 2012 until April 2013. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study was performed at a clinical research centre in healthy female volunteers of reproductive age. The subjects used 2 mg estradiol bid for 24 days in each treatment cycle. Progesterone or placebo was administered vaginally from Day 15 onwards during 10 days. In each treatment period, an endometrial biopsy for histological evaluation was performed on Day 23 and pharmacokinetic parameters were determined after the first progesterone dose on Day 15 and after the last dose on Day 24. MAIN RESULTS AND THE ROLE OF CHANCE: Frequencies of (early and late) secretory transformation of the endometrium, i.e. adequate responses, during treatment with 200 mg and 400 mg vaginal pessaries bid were comparable with those during 90 mg vaginal gel treatment (90-94%), whereas lower secretory transformation rates were observed during treatment with 100 mg bid and 400 mg od (64-75%). At the time of the endometrial biopsy in the cycle the late secretory state of the endometrium, which is characteristic of adequate luteal support, was observed more often with 400 mg pessaries bid (90%) than with vaginal gel (82%) and with lower pessary doses (64-78%). Pharmacokinetic parameters after repeated dosing of vaginal pessaries showed a dose-dependent, but not dose-proportional, increase of plasma progesterone levels. The lowest incidence of bleeding and spotting was reported during treatment with 400 mg pessaries bid. LIMITATIONS REASONS FOR CAUTION: The primary outcome parameter, rate of secretory transformation of the endometrium, is a surrogate for endometrial receptivity and for the actual clinical efficacy. WIDER IMPLICATIONS OF THE FINDINGS: Delivery of progestesterone through 400 mg pessaries bid is an effective alternative method for luteal support in ART. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Actavis Group PTC ehf., Iceland, part of Teva Pharmaceuticals, and L.D. Collins. I.D. and C.K. are directors of Dinox, a contract research organisation. I.K. is Managing Director of Pharmaplex and M.W. is Managing Director of M.A.R.C.O., service organisations involved in organisation/supervision and evaluation/reporting of clinical trials. All received funding for the conduct of the study from Actavis. S.H. and Th.M. are employees of Actavis. TRIAL REGISTRATION NUMBER: EudraCT number 2012-001726-95.


Subject(s)
Endometrium/drug effects , Estriol/administration & dosage , Luteal Phase/drug effects , Progesterone/administration & dosage , Administration, Intravaginal , Adolescent , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Estriol/pharmacokinetics , Female , Humans , Middle Aged , Ovarian Follicle/diagnostic imaging , Pessaries , Progesterone/blood , Progesterone/pharmacokinetics , Vaginal Creams, Foams, and Jellies/administration & dosage , Vaginal Creams, Foams, and Jellies/pharmacokinetics , Young Adult
4.
Climacteric ; 19(2): 172-80, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26786399

ABSTRACT

OBJECTIVES: To investigate the pharmacokinetics, safety and preliminary effectiveness of ultra-low-dose estriol vaginal gel formulations (20 µg/g (T1) and 50 µg/g (T2)) compared to Ovestinon® (estriol 500 µg/0.5 g (R)) and placebo in postmenopausal women. METHODS: Forty-three volunteers were randomly assigned to received T1, T2, R or placebo once daily for 21 days. Absorption of estriol after single and multiple administration was analyzed. Cytological changes in the vagina, tolerability and safety were also investigated. RESULTS: Thirty-six women were included in the pharmacokinetic analysis. Systemic absorption was lower with test formulations (AUC0-t: 171.65 ± 80.18 (T1) and 406.75 ± 199.53 (T2) pg/ml × h) than with Ovestinon® (1221.97 ± 549.06 pg/ml × h). Estriol exposure of the test formulations after multiple administration (AUCss: 36.33 ± 30.52 (T1) and 73.71 ± 46.86 (T2) pg/ml × h) was significantly lower than after single-dose administration and not significantly different between them. In contrast, the exposure after repeated administration of Ovestinon® was considerable and not statistically different from levels after single administration. All estriol formulations produced similar improvement in the vaginal maturation value, while placebo showed a small and not significant change. Overall safety and acceptability were good. CONCLUSIONS: Estriol 20 and 50 µg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®.


Subject(s)
Estriol/administration & dosage , Estriol/pharmacokinetics , Gels , Postmenopause , Administration, Intravaginal , Aged , Atrophy , Biological Availability , Estriol/adverse effects , Female , Humans , Middle Aged , Placebos , Vagina/pathology , Vaginal Creams, Foams, and Jellies/therapeutic use , Vaginal Diseases/drug therapy
5.
Eur J Clin Microbiol Infect Dis ; 34(10): 2023-8, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26223323

ABSTRACT

This study was a detailed microscopic analysis of the changes of vaginal microflora characteristics after application of 0.03 mg estriol-lactobacilli combination on the vaginal ecosystem in postmenopausal breast cancer (BC) survivors on aromatase inhibitors (AI) with severe atrophic vaginitis. A total of 16 BC women on AI applied daily one vaginal tablet of Gynoflor® for 28 days followed by a maintenance therapy of three tablets weekly for 8 weeks. During four follow up visits a smear from the upper lateral vaginal wall was analysed by phase contrast microscopy at 400 times magnification in order to classify the lactobacillary grades(LBG), bacterial vaginosis (BV), aerobic vaginitis (AV), vulvovaginal candidosis (VVC), proportional number of leukocytes and evidence of parabasal cells and epitheliolysis. LBG improved from 81% LBG-III at entry to 88% LBG-I&IIa after 2 weeks of initial therapy, which further improved upon follow up (p < 0.001). Whereas BV was a rare event, AV was frequent and substantially improved during treatment (p < 0.01). While at entry most patients had moderate or severe AV, after maintenance therapy no patient except one had AV. The number of leukocytes dropped dramatically from a score of 1.78 ± 0.70 to 1.06 ± 0.25 which was consistent till the end of the study (p < 0.01). Parabasal cells dropped from a score of 3.4 ± 0.64 at entry to 1.3 ± 0.60 at the final visit (p trend < 0.01). Starting from a low rate of Candida colonisation of 2/14 (14%), a sudden rise to 7/16 (44%) occurred after 2 weeks, to return back to base levels at subsequent visits. The vaginal use of ultra-low dose estriol and lactobacilli results in rapid and enduring improvement of all markers of the vaginal microflora and epithelial vaginal cell quality in women with breast cancer on AI with dyspareunia. Candida may develop soon after its use, but rapidly disappears again upon their prolonged use. Due to its excellent safety profiles and clinical efficacy we recommend this product as first choice in women on AI with severe dyspareunia.


Subject(s)
Aromatase Inhibitors/adverse effects , Breast Neoplasms/drug therapy , Candidiasis, Vulvovaginal/drug therapy , Communicable Diseases/drug therapy , Estriol/administration & dosage , Inflammation/drug therapy , Vaginosis, Bacterial/drug therapy , Administration, Intravaginal , Adult , Biomarkers/blood , Candida/ultrastructure , Ecosystem , Estriol/pharmacokinetics , Female , Humans , Lactobacillus acidophilus/ultrastructure , Middle Aged , Postmenopause , Tablets , Vagina/drug effects , Vagina/microbiology , Vaginal Creams, Foams, and Jellies , Vaginosis, Bacterial/microbiology
6.
Breast Cancer Res Treat ; 145(2): 371-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24718774

ABSTRACT

Phase I pharmacokinetic (PK) study assessed circulating estrogens in breast cancer (BC) patients on a non-steroidal aromatase inhibitor (NSAI) with vaginal atrophy using vaginal ultra-low-dose 0.03 mg estriol (E3) and Lactobacillus combination vaginal tablets (Gynoflor(®)). 16 women on NSAI with severe vaginal atrophy applied a daily vaginal tablet of Gynoflor(®) for 28 days followed by a maintenance therapy of 3 tablets weekly for 8 weeks. Primary outcomes were serum concentrations and PK of E3, estradiol (E2), and estrone (E1) using highly sensitive gas chromatography-mass spectrometry. Secondary outcomes were clinical measures for efficacy and side effects; microscopic changes in vaginal epithelium and microflora; and changes in serum FSH, LH, and sex hormone-binding globulin. Compared with baseline, serum E1 and E2 did not increase in any of the women at any time following vaginal application. Serum E3 transiently increased after the first application in 15 of 16 women, with a maximum of 168 pg/ml 2-3 h post-insertion. After 4 weeks, serum E3 was slightly increased in 8 women with a maximum of 44 pg/ml. The vaginal atrophy resolved or improved in all women. The product was well tolerated, and discontinuation of therapy was not observed. The low-dose 0.03 mg E3 and Lactobacillus acidophilus vaginal tablets application in postmenopausal BC patients during AI treatment suffering from vaginal atrophy lead to small and transient increases in serum E3, but not E1 or E2, and therefore can be considered as safe and efficacious for treatment of atrophic vaginitis in BC patients taking NSAIs.


Subject(s)
Aromatase Inhibitors/adverse effects , Atrophy/drug therapy , Breast Neoplasms/drug therapy , Estriol/administration & dosage , Estriol/pharmacokinetics , Lactobacillus acidophilus , Vagina/pathology , Administration, Intravaginal , Aromatase Inhibitors/therapeutic use , Atrophy/chemically induced , Estradiol/blood , Estriol/blood , Female , Humans , Middle Aged , Postmenopause , Tablets , Treatment Outcome , Vagina/drug effects , Vagina/microbiology
7.
Maturitas ; 74(4): 375-82, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23384975

ABSTRACT

OBJECTIVE: Bioidentical compounded hormone therapy is popular among patients, but providers do not have pharmacokinetic information or dosing guidelines for these preparations. Our objective was to compare the pharmacokinetics of the commonly used compounded preparations with conventional hormonal preparations that are considered bioequivalent in practice. METHODS: We conducted a randomized, blinded, four-arm 16-day clinical trial of forty postmenopausal women assigned to one of three doses of a compounded estrogen cream (Bi-est (80:20); 2.0, 2.5, or 3.0 mg)+compounded oral progesterone 100 mg, or to a conventional estradiol patch (Vivelle-Dot™ 0.05 mg)+Prometrium™ 100mg. Serum levels of estrone, estradiol, estriol, and progesterone were obtained at multiple time intervals during the first 24-h, and at steady-state. RESULTS: Results were analyzable for 37/40 women. Study medications were well tolerated. The AUC at 24h and at steady-state for estrogens remained consistently lower for all doses of Bi-est tested relative to the patch. The difference was statistically significant for Bi-est 2.0mg (AUC-estradiol=181 vs. 956; p<0.001) and 2.5mg (AUC-estradiol=286 vs. 917; p<0.001). Estriol levels remained low in all study arms. Serum progesterone levels were comparable in conventional vs. compounded groups. CONCLUSIONS: This pharmacokinetic trial showed that the currently used doses of compounded hormones yield lower levels of estrogen compared to the standard-dose estradiol patch. To find comparable doses, further studies are needed. This successfully conducted randomized controlled study attests to the feasibility of using a similar design in the setting of a larger clinical trial.


Subject(s)
Estradiol/pharmacokinetics , Estriol/pharmacokinetics , Estrogen Replacement Therapy/methods , Progesterone/pharmacokinetics , Adult , Area Under Curve , Double-Blind Method , Estradiol/administration & dosage , Estradiol/blood , Estriol/administration & dosage , Estriol/blood , Female , Humans , Middle Aged , Postmenopause , Progesterone/administration & dosage , Progesterone/blood
8.
Arzneimittelforschung ; 62(8): 378-83, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22692777

ABSTRACT

UNLABELLED: A prospective monocentric open-label and single-arm trial was performed in 19 postmenopausal women with diagnosed vaginal atrophy. The aim was to determine the extent of a systemic exposure to estriol (CAS 50-27-1). Administration of estriol containing pessaries was daily for 21 days. In order to establish a pharmacokinetic profile after single as well as multiple vaginal doses of 0.03 mg estriol blood samples were taken after the first vaginal administration as well as at day 21 after the last administration. Moreover, in order to control for accumulation additional blood samples were taken predose at days 6, 11 and 16. RESULTS: The initial administration increased the population mean estriol plasma concentration to a maximum of 42.1 pg/ml 1 h after dosing. However, already 12 h after administration the estriol concentration had again dropped below 5 pg/ml (lower limit of quantification) in all patients. Repeated administration did not result in an accumulation of estriol, since 2 h after application of the 21st pessary, the population mean estriol concentration reached a maximum of only 11.9 pg/ml. Moreover, no severe or serious adverse events occurred, and no clinically relevant findings were reported. CONCLUSION: Single vaginal application of pessaries containing 0.03 mg estriol resulted in a very low systemic bioavailability, which decreased even more after multiple dosing confirming a favourable safety profile of low dose pessaries administered daily over 21 days.


Subject(s)
Estriol/pharmacokinetics , Pessaries , Administration, Intravaginal , Aged , Biological Availability , Estriol/administration & dosage , Estriol/adverse effects , Female , Humans , Middle Aged , Prospective Studies
9.
Gynecol Obstet Invest ; 66(2): 111-8, 2008.
Article in English | MEDLINE | ID: mdl-18446040

ABSTRACT

BACKGROUND/AIMS: There is a lack of evidence in the literature supporting vaginal application of a combination hormone-containing cream for local and systemic symptom relief. This pilot study examined the extent of absorption of a single cream containing estriol, estradiol, progesterone, DHEA, and testosterone. METHODS: A combination cream was administered to 12 postmenopausal women in two differing doses over two independent time periods. Following 28 days (arm 1) and an additional 14 days (arm 2), measurement of hormones in saliva and blood and measurements of symptom relief, patient tolerability, and health-related quality of life (HRQoL) were obtained. RESULTS: The dosage and time of evaluation for study arm 1 was not ideal for providing documented increases in hormone levels. HRQoL measurements supported measured improvement in this arm. The second arm did document absorption of the various hormones when given vaginally. CONCLUSION: This study is the first documenting systemic absorption of multiple hormones by both saliva and blood as well as improvement of HRQoL. This therapy was generally well-tolerated with only 2 patients experiencing minor irritation, not necessitating discontinuation. Additional studies in larger numbers of patients will provide better knowledge for clinicians wanting to provide similar therapy at the lowest effective dose.


Subject(s)
Gonadal Steroid Hormones/administration & dosage , Gonadal Steroid Hormones/pharmacokinetics , Hormone Replacement Therapy/methods , Mucous Membrane/metabolism , Vagina/metabolism , Administration, Intravaginal , Adsorption , Aged , Dehydroepiandrosterone/administration & dosage , Dehydroepiandrosterone/blood , Dehydroepiandrosterone/pharmacokinetics , Emollients/administration & dosage , Emollients/pharmacokinetics , Estradiol/administration & dosage , Estradiol/blood , Estradiol/pharmacokinetics , Estriol/administration & dosage , Estriol/blood , Estriol/pharmacokinetics , Female , Gonadal Steroid Hormones/blood , Humans , Middle Aged , Pilot Projects , Quality of Life , Saliva/metabolism , Testosterone/administration & dosage , Testosterone/blood , Testosterone/pharmacokinetics
10.
Br J Cancer ; 90(4): 932-7, 2004 Feb 23.
Article in English | MEDLINE | ID: mdl-14970876

ABSTRACT

2-Methoxyoestradiol (2-MeOE2) is an endogenous oestrogen metabolite that inhibits the proliferation of cancer cells in vitro, and it is also antiangiogenic. In vivo 2-MeOE2, when administered at relatively high doses, inhibits the growth of tumours derived from breast cancer cells, sarcomas and melanomas. Sulphamoylated derivatives of 2-MeOE2 are more potent inhibitors of in vitro breast cancer cell growth than 2-MeOE2. In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats. Their ability to inhibit tumour growth was compared in nude mice bearing xenografts derived from MDA-MB-435 (oestrogen receptor negative) melanoma cancer cells. After a single oral 10 mg kg(-1) dose of 2-MeOE2bisMATE, significant concentrations of this compound were still detectable at 24 h. In contrast, no 2-MeOE2 or metabolites were detected in plasma at any time after a 10 mg kg(-1) oral dose. Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%. No significant metabolites of 2-MeOE2bisMATE were detected in plasma after oral or intravenous dosing, showing that this drug is resistant to metabolism. In the tumour efficacy model, oral administration of 2-MeOE2bisMATE, at 20 mg kg(-1) day(-1) daily for 28 days, almost completely inhibited tumour growth. Inhibition of tumour growth was maintained for a further 28 days after the cessation of dosing. At this dose level, 2-MeOE2 did not inhibit tumour growth. The resistance to metabolism shown by 2-MeOE2bisMATE and its ability to inhibit tumour growth in vivo suggest that this compound should have considerable potential for development as a novel anticancer drug.


Subject(s)
Estradiol/analogs & derivatives , Estradiol/pharmacology , Estradiol/pharmacokinetics , Estriol/analogs & derivatives , Estriol/pharmacology , Estriol/pharmacokinetics , Melanoma/drug therapy , Skin Neoplasms/drug therapy , 2-Methoxyestradiol , Administration, Oral , Animals , Biological Availability , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Dose-Response Relationship, Drug , Estradiol/administration & dosage , Estriol/administration & dosage , Female , Melanoma/veterinary , Mice , Mice, Nude , Rats , Skin Neoplasms/veterinary , Transplantation, Heterologous
11.
Res Vet Sci ; 75(1): 55-9, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12801463

ABSTRACT

The aim of the present study was to investigate the pharmacokinetics of oestriol in plasma in the dog after repeated oral administration of oestriol tablets, a preparation intended for the treatment of urinary incontinence in the bitch. The study was performed in six healthy, entire, adult female beagle dogs. The bitches were treated once daily with two tablets, containing 1 mg oestriol per tablet, for seven consecutive days (days 1-7). Blood samples were taken from the jugular vein before treatment, frequently on days 1, 3 and 7 of the treatment period and daily just before (C(trough)) and 1 h after dosing (C(t=1h)). During the washout period samples were taken at a 24 h interval up to four days post-treatment. Oestriol concentrations were determined in plasma by radioimmunoassay. Pharmacokinetic parameters, AUC, C(max) and t(max), were determined from the plasma concentration-time curves using non-compartmental methods. The between animal variation in C(max) and the AUC was high. Individual values of the C(max) varied from 206 pg/ml (day 1) to 1128 pg/ml (day 7) and the AUC(0-24h) from 789 pg x h/ml (day 1) to 5718 pg x h/ml (day 7). t(max) occurred within 1 h. The mean C(trough) value was slightly above the pre-treatment level ( 38+/-2 pg/ml vs. 18+/-5 pg/ml). Within 48 h after the last treatment the concentrations had returned to the pre-treatment values. C(max) and C(trough) did not increase during the treatment period, indicating that no accumulation occurred. A shoulder in the concentration-time curve around 8-12 h after treatment strongly suggested the existence of enterohepatic recirculation (EHR). The average relative contribution of the EHR to the AUC(0-24h) was estimated to be 22%, 38% and 44% on days 1, 3 and 7, respectively. These mean values were calculated from five animals per time point, because one dog failed to show EHR on days 1 and 3 and was therefore excluded from the calculations.


Subject(s)
Dogs/metabolism , Estriol/pharmacokinetics , Administration, Oral , Animals , Dogs/blood , Estriol/blood , Female , Urinary Incontinence/drug therapy , Urinary Incontinence/veterinary
12.
Zentralbl Gynakol ; 123(9): 505-12, 2001 Sep.
Article in German | MEDLINE | ID: mdl-11709743

ABSTRACT

OBJECTIVE: The aim of this randomized cross-over study was the comparison between a sequential 28-day hormone replacement therapy (HRT) using micronized estradiol and a cyclic 21-day HRT using estradiol valerate with regard to the pharmacokinetics of estradiol. - MATERIAL AND METHODS: Fifty postmenopausal women were randomly assigned to be treated either with Trisequens(R) for 28 days or with Sisare(R) for 21 days. After a wash-out cycle, the women were treated for one cycle with the other preparation in a cross-over fashion. The pharmacokinetic profile of the serum concentrations of estradiol was measured on day 1, 21 and 28 each immediately before and 1, 2, 4, 6, 8, and 10 hours after intake of a tablet, and the AUC (area under the curve) was calculated. - RESULTS: The serum concentrations of estradiol increased from a mean of 10 pg/ml up to 40 pg/ml (Trisequens(R)) and 30 pg/ml (Sisare(R)) on day 1, and to 80 pg/ml (Trisequens(R)) and 60 pg/ml (Sisare(R)) on day 21, and declined to 40 pg/ml (Trisequens(R)) and 10 pg/ml (Sisare(R)) on day 28. The AUC as calculated from both treatment cycles, was significantly higher on day 1, 21, and 28 during treatment with Trisequens(R) than with Sisare(R). This difference was, however, not signifcant on day 1 and 21 of the first treatment cycle. - CONCLUSION: During treatment with 2 mg micronized estradiol the serum concentrations are significantly higher than with 2 mg estradiol valerate. On day 28 of treatment with Sisare(R), the estradiol levels decline to baseline values, while using Trisequens(R) they remain in the range of those measured on day 1.


Subject(s)
Estradiol/analogs & derivatives , Estradiol/pharmacokinetics , Estrogen Replacement Therapy/methods , Norethindrone/analogs & derivatives , Postmenopause , Aged , Contraceptives, Oral, Sequential/pharmacokinetics , Cross-Over Studies , Drug Combinations , Estradiol/blood , Estriol/pharmacokinetics , Estrogen Replacement Therapy/adverse effects , Female , Humans , Immunoassay/methods , Luminescent Measurements , Middle Aged , Norethindrone/pharmacokinetics
13.
Arch Pharm Res ; 23(5): 513-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11059833

ABSTRACT

Enterohepatic recycling of estrogen after oral administration of 1 mg non-radioactive estriol was studied in fourteen women selected as the control subjects and ten infertile women in whom the infertility was appearing to be of endocrine origin. The extent of enterohepatic recycling of estriol (E3) during the early follicular phase of menstrual cycle was assessed by monitoring during 48 h the urinary excretion of its two major metabolites i.e; estriol 16 alpha-glucuronide (E3-16 alpha-CG) and estriol-3 glucuronide (E3-3-G). The change in urinary level of E3-3-G with respect to E3-16 alpha-G was considered to reflect the extent of enterohepatic recycling of estriol. Lower values of urinary output of both metabolites in the infertile women as compared with the control subjects and the urinary excretion profile of both metabolites during 48 h after estriol ingestion reveal that the reduced extent of enterohepatic recycling could possibly be one of the factors which contribute towards the incidence of infertility in women.


Subject(s)
Estriol/pharmacokinetics , Infertility, Female/metabolism , Liver/metabolism , Adolescent , Adult , Female , Humans , Infertility, Female/etiology
14.
J Pharm Biomed Anal ; 18(1-2): 187-92, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9863957

ABSTRACT

A fluorimetric liquid chromatographic method (lambda(ex) = 280 nm; lambda(em) = 312 nm) was developed for measurements of unconjugated estrogens (estradiol and estriol) in pharmaceutical dosage forms using a reversed-phase column with water acetonitrile at different composition as mobile phase. The in vitro release profiles of three different estradiol transdermal therapeutic systems were determined through a medical-grade silicone rubber subdermal implant material membrane, using a modified Franz diffusion apparatus at 37 degrees C in presence of PEG 400. The HPLC method possesses advantages of rapidity, simplicity and accuracy.


Subject(s)
Chemistry, Pharmaceutical/methods , Estradiol/analysis , Estriol/analysis , Administration, Cutaneous , Chromatography, High Pressure Liquid , Estradiol/pharmacokinetics , Estriol/pharmacokinetics , Ointments/metabolism , Spectrometry, Fluorescence , Tablets/metabolism
15.
Altern Med Rev ; 3(2): 101-13, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9577246

ABSTRACT

While conventional hormone replacement therapy provides certain benefits, it is not without significant risks. Estriol has been found to provide some of the protection without the risks associated with stronger estrogens. Depending upon the situation, estriol may exert either agonistic or antagonistic effects on estrogen. Estriol appears to be effective at controlling symptoms of menopause, including hot flashes, insomnia, vaginal dryness, and frequent urinary tract infections. Results of research on its bone-density-maintaining effects have been contradictory, with the most promising results coming from Japanese studies. Estriol's effect on cardiac risk factors has also been somewhat equivocal; however, unlike conventional estrogen prescriptions, it does not seem to contribute to hypertension. Although estriol appears to be much safer than estrone or estradiol, its continuous use in high doses may have a stimulatory effect on both breast and endometrial tissue.


Subject(s)
Estriol/therapeutic use , Estrogen Replacement Therapy , Menopause/drug effects , Estriol/pharmacokinetics , Estrogens/metabolism , Female , Heart Diseases/prevention & control , Humans , Osteoporosis, Postmenopausal/prevention & control , Skin/drug effects , Urologic Diseases/drug therapy , Vaginitis/drug therapy
16.
Rev. méd. Chile ; 126(5): 481-7, mayo 1998. ilus
Article in Spanish | LILACS | ID: lil-216431

ABSTRACT

Background: Estradiol (E2) has a potent antioxidant effect on low density lipoproteins (LDL) in vitro and in vivo, which could be important in explaining the cardioprotective effect of hormone replacement therapy (HRT) in post menopausal women. Estriol (E3), on the other hand, is a weak estrogen with low metabolic effects on different tissues, and at present no cardioprotective effect has been attributed to this steroid. Aim: To study the antioxidant effect of E3 on LDL and to compare it with the potent antioxidant action exhibited by E2. Subjects and methods: After LDL was isolated by ultra centrifugation from plasma of 12 healthy untreated post menopausal women, it was divided into aliquots containing 0.5 mg of LDL protein. Estriol and E2 in doses of 0, 1, 5, 15 and 50 µM were incubated with different aliquots of LDL. CuSO4 15 µM was added to each aliquot to induce an oxidative stress. The aliquots were then incubated during 4 hours at 37 ­C. Malonaldehyde (MDA) was measured as a marker of LDL oxidation, and expressed as nM/mg protein. Results (mean ñ SD): Estriol induced a dose-dependent decrease in MDA concentration (baseline 62.8 ñ 21.7; 1 µM: 61.5 ñ 23.0; 5 µM: 52.9 ñ 20,3; 15 µM 43.5 ñ 20.1 and 50 µM: 31.0 ñ 17.6 nM/mg protein; F= 92.4; p< 0.0001), reaching a mean decrease of 50.7 percent at the highest dose tested. Estradiol has a similar dose-dependent decrease in MDA concentration (F= 60.2; p< 0.0001), revealing a more potent effect than E3 (p< 0.05), with a mean decrease of 67.4 percent at the highest dose tested. Conclusions: Our results demonstrate that estriol shows an important antioxidant action of LDL in vitro, although its effect is less potent than estradiol. These results raise the possibility that estriol could have a cardioprotective effect in post menopausal women, possibility that has not been yet demonstrated


Subject(s)
Humans , Female , Middle Aged , Postmenopause/drug effects , Estradiol/pharmacokinetics , Estriol/pharmacokinetics , Lipoproteins, LDL , Lipid Peroxidation , Cardiovascular Diseases , Antioxidants/pharmacokinetics , Malondialdehyde/blood
17.
Rev. chil. obstet. ginecol ; 62(5): 336-42, 1997.
Article in Spanish | LILACS | ID: lil-211947

ABSTRACT

La mamografía constituye el método de mayor sensibilidad en el diagnóstico precoz de cáncer de mama y en especial en las mujeres mayores, con mamas tipo "Radiolúcidas". Es de indicación absoluta en mujeres candidatas a recibir HTR y para su seguimiento. La relación entre la HTR y el riesgo de desarrollar un cáncer de mama es un tema controversial aún no resuelto. Sin embargo estudios recientes señalan que la HTR puede inducir un aumento de la densidad mamográfica (DxMx). El aumento de la DxMx ha sido identificado como uno de los factores asociados a fallas en el Screening de cáncer de mama. El objetivo de nuestro estudio, realizado en 2 centros mamográficos privados, fue evaluar las modificaciones de la DxMx en 210 pacientes que recibían distintos esquemas de HTR durante 1 año de observación. Se dividieron en 7 grupos terapéuticos de 30 pacientes cada uno y se compararon contra un grupo control de similares características. Para cuantificar las modificaciones de la DxMx se usaron los patrones de Wolfe. Considerando los 7 grupos de tratamiento en forma global se obtuvo un aumento de la DxMx en un 32,3 por ciento. El grupo Tibolona y Estriol presentó el menor porcentaje de cambios en la DxMx y fue similar al grupo control sin HTR. El mayor porcentaje de aumento en la DxMx se observó en los grupos que recibieron valerianato de estradiol (E2) en forma exclusiva o en esquema secuencial con MPA (66,7 por ciento) y 56,7 por ciento respectivamente). El grupo que recibió estrógenos conjugados en forma exclusiva mostró un aumento de la DxMx de un 43 por ciento y el grupo con estrógenos conjugados más MPA secuencial la DxMx aumentó en un 26,7 por ciento. El grupo que recibió esquema continuo combinado con valerianato de estradiol más MPA (2,5 mg) evidenció un aumento de la DxMx de un 30 por ciento. Estos resultados señalan la necesidad de agregar al informe Mx los cambios observados en la DxMx como consecuencia de la HTR ya que permite al clínico adecuar los esquemas terapéuticos a la respuesta individualizada de cada mujer


Subject(s)
Humans , Female , Middle Aged , Breast Neoplasms , Mammography/statistics & numerical data , Estrogen Replacement Therapy/adverse effects , Body Mass Index , Estradiol/pharmacokinetics , Estriol/pharmacokinetics , Estrogens, Conjugated (USP)/pharmacokinetics , Longitudinal Studies , Progesterone/pharmacokinetics , Retrospective Studies
18.
Contraception ; 54(4): 235-42, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8922877

ABSTRACT

It was the aim of the study to compare the pharmacokinetic properties of the two new estrogens, ZK 136295 and ZK 115194, with those of ethinylestradiol (EE2) after single intravenous (60 micrograms) and oral (120 and 240 micrograms) administration in 54 postmenopausal women. In particular, our objective was to examine whether one or both compounds were characterized by an improved oral bioavailability with less inter-subject variability than EE2. Drug serum concentrations were determined using specific radioimmunoassays for EE2 and ZK 136295, and a GC/MS/MS-method for ZK 115194. Following i.v. administration of the new estrogens and of EE2, the drugs were rapidly distributed in the body. The mean terminal half-lives were calculated to be 12.3 +/- 12.4, 28.7 +/- 9.6, and 26.1 +/- 11.1 h for ZK 136295, ZK 115194, and EE2 respectively. After oral administration of 120 micrograms, the absolute bioavailability was calculated to be about 40% for ZK 136295 as well as for EE2 with a high inter-individual variation (variation coefficient: 44 and 67%). By doubling the dose, the systemic availability increased dose-dependently for both drugs to about 70% with the same high inter-individual variation. Following single oral administration of 240 micrograms ZK 115194, the absolute bioavailability amounted to 33 +/- 19%. The present study clearly revealed that although the two new estrogens differed considerably in their pharmacokinetic behavior, they demonstrated a reduced and highly variable systemic availability similar to that of EE2.


PIP: Researchers with the pharmaceutical manufacturer Schering AG in Berlin, Germany, conducted a double-blind clinical trial in 54 healthy, postmenopausal women to compare the pharmokinetic properties of two new estrogens (ZK 136295 and ZK 115194) with those of ethinyl estradiol (EE2). Specifically, they examined whether one or both of the new estrogens improved bioavailability with less inter-subject variability than EE2. The dosage included single intravenous (60 mcg) and oral (120 and 240 mcg) administration. ZK 115195 differs from natural estradiol by 14alpha, 17alpha-bridging, which should prevent early metabolic degradation during absorption and passage through the liver. ZK 136295 is the corresponding derivative of endogenous estriol. All three compounds were rapidly distributed throughout the body. ZK 136295 had the shortest mean terminal half-life; ZK 115194 had the longest (12.3 vs. 28.7 hours); and EE2 had a mean terminal half-life of 26.1 hours. Oral administration of 120 mcg effected an absolute bioavailability of about 40% for ZK 136295 and EE2. The inter-individual variation was high (variation coefficient = 44% and 67%) for both compounds. When the oral dose was 240 mcg, systemic availability increased dose-dependently for ZK 136295 and EE2 to around 70% with the same high inter-individual variation. Oral administration of 240 mcg of ZK 115194 effected an absolute bioavailability of about 33%. These findings show that the 14alpha, 17alpha-bridging of estradiol does not result in a higher bioavailability than that achieved by introduction of a 17alpha-ethinyl group. Yet, increasing the dose of ZK 115194 and of EE2 from 120 to 240 mcg increased their absolute bioavailability two-fold. In conclusion, even though the pharmacokinetic behavior of the two new estrogens differed markedly, the two estrogens exhibited a reduced and highly variable systemic availability similar to that of EE2.


Subject(s)
Estradiol Congeners/pharmacokinetics , Estradiol/analogs & derivatives , Estrogens/pharmacokinetics , Ethinyl Estradiol/pharmacokinetics , Postmenopause/metabolism , Administration, Oral , Aged , Biological Availability , Cohort Studies , Cross Reactions , Double-Blind Method , Estradiol/administration & dosage , Estradiol/blood , Estradiol/chemistry , Estradiol/pharmacokinetics , Estradiol Congeners/administration & dosage , Estradiol Congeners/blood , Estradiol Congeners/chemistry , Estriol/administration & dosage , Estriol/analogs & derivatives , Estriol/blood , Estriol/pharmacokinetics , Estrogens/administration & dosage , Estrogens/blood , Estrogens/chemistry , Ethinyl Estradiol/administration & dosage , Ethinyl Estradiol/blood , Ethinyl Estradiol/chemistry , Female , Half-Life , Humans , Injections, Intravenous , Middle Aged , Postmenopause/blood , Postmenopause/drug effects , Radioimmunoassay , Reference Standards , Time Factors
19.
Nucl Med Biol ; 22(5): 547-53, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7581162

ABSTRACT

We tried to put the estrogen metabolite to use in tumor imaging. The antibody against estriol 3-sulfate (E3 3-S), which was one of the major metabolites of estrogen in hormone-dependent mammary carcinoma, was prepared and the tissue distribution and imaging of human breast carcinoma with anti-E3 3-S antibody (Ab) were studied in nude mice. In hormone-dependent breast carcinoma, MCF-7,-bearing nude mice, [125I] anti-E3 3-S Ab localized in tumor with the percentage injected dose/g of 9.29 +/- 3.01 (mean +/- SD). This value was significantly high compared with that in hormone-independent breast carcinoma, MDA-MB-231,-bearing nude mice. At 72 h after the administration of [125I]anti-E3 3-S Ab to MCF-7 bearing mice, tumor/blood, tumor/liver and tumor/muscle ratios were 0.49, 5.02 and 6.83, respectively. These ratios were supposed to be enough for imaging. In radioimmunoscintigraphy, a MCF-7 tumor was clearly visualized at 120 or 168 h post-injection of [131I]anti-E3 3-S Ab.


Subject(s)
Estriol/analogs & derivatives , Mammary Neoplasms, Experimental/diagnostic imaging , Neoplasms, Hormone-Dependent/diagnostic imaging , Animals , Diagnosis, Differential , Estriol/pharmacokinetics , Female , Humans , Iodine Radioisotopes , Isotope Labeling , Mammary Neoplasms, Experimental/diagnosis , Mammary Neoplasms, Experimental/physiopathology , Mice , Mice, Nude , Neoplasms, Hormone-Dependent/diagnosis , Neoplasms, Hormone-Dependent/physiopathology , Radioimmunodetection , Tissue Distribution
20.
Gynecol Obstet Invest ; 38(2): 113-16, 1994.
Article in English | MEDLINE | ID: mdl-7959337

ABSTRACT

As there are no proven optimal serum estradiol levels, we sought to evaluate the pharmacokinetic profiles of serum estradiol levels following a single oral dose of 2 mg estradiol and 1 mg of estriol (Trisequens) among 26 surgically induced, postmenopausal patients. Their serum estradiol levels were periodically measured over 24 h following oral administration of the drug. They were divided into two groups according to the computed hourly mean estradiol values: group A, < 250 pg/ml/h ( < 918 pmol/l/h) and group B, > 250 pg/ml/h ( > 918 pmol/l/h). The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001). The mean total area under the curve in group A was 4,887 pg/ml (17,940 pmol/l), which was significantly lower than that of 7,995 +/- 652 pg/ml/24 h (29,350 +/- 2,393 pmol/l/24 h) found for group B (p < 0.001). The mean body mass index showed a significant difference (p < 0.003) between group A and group B (29.4 +/- 0.56 vs. 24.3 +/- 0.24). We found that 57% of our patients were exposed to excessively high levels of estradiol during the 24-hour period following drug ingestion. We advise monitoring estradiol levels and individualizing estrogen replacement therapy, to avoid the long-term exposure of postmenopausal patients to superphysiological estradiol levels.


Subject(s)
Estradiol/administration & dosage , Estriol/administration & dosage , Estrogen Replacement Therapy , Norethindrone/analogs & derivatives , Adult , Body Mass Index , Drug Combinations , Estradiol/blood , Estradiol/pharmacokinetics , Estriol/pharmacokinetics , Female , Humans , Middle Aged , Norethindrone/administration & dosage , Norethindrone/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...